Difference between revisions of "Epirubicin (Ellence)"
Jump to navigation
Jump to search
m (→Also known as) |
m |
||
| Line 14: | Line 14: | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
*[[Osteosarcoma]] | *[[Osteosarcoma]] | ||
| + | *[[Pancreatic cancer]] | ||
*[[Small cell lung cancer]] | *[[Small cell lung cancer]] | ||
*[[Soft tissue sarcoma]] | *[[Soft tissue sarcoma]] | ||
| Line 24: | Line 25: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 9/15/1999: Initial | + | * 9/15/1999: Initial approval as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary [[Breast cancer | breast cancer]]. |
==Also known as== | ==Also known as== | ||
| Line 48: | Line 49: | ||
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
[[Category:Osteosarcoma medications]] | [[Category:Osteosarcoma medications]] | ||
| + | [[Category:Pancreatic cancer medications]] | ||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
[[Category:Soft tissue sarcoma medications]] | [[Category:Soft tissue sarcoma medications]] | ||
Revision as of 11:55, 24 April 2019
General information
Class/mechanism: Anthracycline; binds and intercalates DNA, which triggers DNA cleavage by topoisomerase II; inhibits DNA/RNA synthesis. Inhibits DNA helicase activity, preventing enzymatic separation of double-stranded DNA.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Breast cancer
- Cholangiocarcinoma
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Gastric cancer
- Hodgkin lymphoma
- Osteosarcoma
- Pancreatic cancer
- Small cell lung cancer
- Soft tissue sarcoma
- Testicular cancer
Patient drug information
- Epirubicin (Ellence) patient drug information (Chemocare)[3]
- Brief patient counseling information can be found on pages 15-16 of the Epirubicin (Ellence) package insert[1]
- Epirubicin (Ellence) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 9/15/1999: Initial approval as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
Also known as
- Generic name: epidoxorubicin
- Brand names: Alrubicin, Anthracin, Binarin, Bioepicyna, Crisabon, E.P.R Elvetium, Ellence, Epidoxo, Epifil, Epilem, Epirubicine, Epizin, Epricin, Eracin, Famorubicin, Farmorubicin, Farmorubicina, Farmorubicine, Pharmorubicin, Riboepi, Rubifarm
References
Categories:
- Drugs
- Intravenous medications
- Vesicant chemotherapy
- Anthracyclines
- Topoisomerase inhibitors
- DNA synthesis inhibitors
- Breast cancer medications
- Cholangiocarcinoma medications
- Diffuse large B-cell lymphoma medications
- Esophageal cancer medications
- Gastric cancer medications
- Hodgkin lymphoma medications
- Osteosarcoma medications
- Pancreatic cancer medications
- Small cell lung cancer medications
- Soft tissue sarcoma medications
- Testicular cancer medications
- FDA approved in 1999